PharmD Info

A forum for Indian Pharmacy Professionals

New Drug Information's and other safety information, drug label changes, and Dose and Dosage Calculations, CDCSO,PvPI and FDA Safety Alerts and etc.
  • User avatar
#2032
Drug-eluting stents (DES) were designed to reduce in-stent neointimal proliferation, and thus,minimise in-stent restenosis (ISR), which is the major disadvantage of percutaneous coronary interventions with bare-metal stents (BMS). DES have revolutionised the treatment of coronary artery disease by reducing the rate of ISR from 20-40% with BMS to 6-8% with DES.

In recent years, however, concern has been raised regarding the long-term safety of DES and the risk of stent thrombosis (ST) and late restenosis due to neoatherosclerosis. This potential increased risk remains an area of uncertainty in the field of interventional cardiology.

DES consist of a standard metallic stent, a polymer coating, and an antiproliferative drug that is embedded within a durable or biodegradable (bioabsorbable) polymer and released over time. Although the common basic concept of DES remains constant, all DES are not made equal and each type may vary significantly with respect to deliverability, efficacy, and safety.

Image


Image
Similar Topics
Topics Statistics Last post
0 Replies 
3500 Views
by Admin
05 Jan 2020, 08:59
0 Replies 
2624 Views
by Admin
06 Oct 2016, 16:59
FDA - Drug Safety Podcasts
by unbreakable  - 16 May 2018, 14:40  - In: Drug Information
0 Replies 
4190 Views
by unbreakable
16 May 2018, 14:40
Prescription Drug Abuse
by unbreakable  - 02 Feb 2018, 16:11  - In: Drug Information
0 Replies 
3904 Views
by unbreakable
02 Feb 2018, 16:11
Drug profile Format- Example
by Admin  - 04 Dec 2018, 10:59  - In: Drug Information
0 Replies 
6316 Views
by Admin
04 Dec 2018, 10:59

This is an online survey to know the best pharmace[…]

Sun Pharma - In this post we listed all the import[…]

Login or Register the KSPC - Kerala State Pharmacy[…]

PCI - Pharmacy Council of India approves the pharm[…]

Join Us Today